Business
Buffett's rising sun: The oracle of Omaha's latest investments are paying off

Buffett's rising sun: The oracle of Omaha's latest investments are paying off

The architect and the contractor

At 93 years young, Warren Buffett has penned his annual letter to Berkshire Hathaway shareholders. A plain-spoken update on the company’s results, filled with his usual folksy investment musings, the letter reads like many of the 58 that came before it, with one exception — a tribute to his business partner Charlie Munger, who passed away in November at 99, in which Buffett credits Munger as the true architect of Berkshire Hathaway.

Elsewhere in the letter, it's business as usual, with Buffett eschewing much discussion of the “bottom line” (net income) his company has to report, instead focusing, as always, on the underlying operating earnings of the collection of businesses, which were up 21% on the prior year.

Buffett’s rising sun

The billionaire businessman also spends a considerable amount of time explaining the company’s investments in 5 Japanese trading firms that have recently soared in value, as the Japanese stock market makes headlines for finally getting back to the record high it achieved back in 1989.

Buffett revealed that Berkshire first started investing in these firms — which themselves have sprawling interests in “unglamorous” industries such as mining and energy — back in 2019, when Japan’s stock market was far from being attractive to global investors. That bet didn’t pay off initially, but, like so many of Berkshire’s investments over the years, it's since come to bear fruit.

Indeed, since August 2019, the share prices of those 5 trading houses are now up 216% on average. Buffett has always bet on America, but now the company’s largest ever aggregate investment outside of the US is paying off handsomely, too.

More Business

See all Business
LA Auto Show

Rivian just had its best day ever on the stock market, after more than 4 years of pain

The EV-maker’s software division helped power a strong Q4, as industry giants pump the brakes on their electric ambitions.

business
Tom Jones

Warner Bros. board members reportedly consider reopening deal talks with Paramount

Paramount’s latest amended bid for Warner Bros. Discovery has finally given the board members of the entertainment conglomerate something to seriously think about, after Bloomberg reported over the weekend that WBD is now considering reopening negotiations with Paramount, despite striking an ~$83 billion binding deal with Netflix in early December.

With the market closed yesterday, Paramount and Warner Bros. Discovery investors are just now getting the chance to react to the news, with the stocks up around 3% and 1% in premarket trading, respectively.

Last Tuesday, Paramount announced that it had enhanced its all-cash $30-per-share bid for Warner Bros., adding an offer to cover the $2.8 billion breakup fee the company would incur with Netflix, as well as a $0.25-per-share “ticking fee” for every quarter the deal hasn’t closed after the end of 2026. Despite Paramount (again) not boosting the bid’s headline cash offer, these latest terms, as well as an offer to backstop a Warner Bros. debt refinancing, have apparently proven enough to give at least some board members pause for thought.

Indeed, top brass at the HBO owner are mulling the possibility that Paramount’s boosted offer could lead to a better deal down the line, Bloomberg reported, citing people familiar with the board’s latest thinking. Still, whether that means the WBD board is hoping for a better bid from Paramount themselves — or the streamer they’ve currently got a binding deal with — is another matter entirely.

Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.